An Ultrasensitive molecular Test may Reveal Hidden Tuberculosis Burden, suggests research
A study published in Nature Communications has found that a highly sensitive molecular assay detected Mycobacterium tuberculosis DNA (TB-DNA) in a notable proportion of hospitalized patients, suggesting the presence of previously undetected forms of TB. Using an ultrasensitive test capable of identifying TB below standard diagnostic limits, researchers from Boston University analyzed 146 respiratory samples and additional controls, highlighting potential gaps in current TB detection methods. The study was conducted by Edward C. and colleagues.
The period under review extended over six years, during which the scientific group carried out three different clinical tests on a total of 297 subjects (N = 297). The scientific approach involved analyzing respiratory samples from two large Boston hospitals in anonymous form. The reason for such a design lies in the nature of the diagnostic method applied, which is based on the detection of extremely small amounts of M. tuberculosis DNA using an ultrasensitive molecular assay that traditional smear microscopy and culture techniques would not be able to find.
Besides conducting a retrospective examination of samples provided by hospitals, the scientists decided to carry out a longitudinal observation to examine any clinical correlations and patient outcomes. This step was taken in order to start correlating the results with medical conditions.
Key findings:
- Among other interesting facts about the research, it should be noted that there was an interesting correlation made between TB-DNA and sickle cell disease. In particular, the presence of TB-DNA was found in a subset of patients suffering from SCD.
- Acute chest syndrome, or ACS, is a potentially lethal condition in which there is fever, chest pain, and chest X-ray abnormalities.
- Although normally associated with infectious complications, fat embolism, or vaso-occlusion, the presence of Mycobacterium tuberculosis DNA indicates that a potential contribution to the development of the syndrome can be made by a paucibacillary form of TB.
- This finding is especially important because it contradicts the traditional clinical picture of TB. If there is a contribution made by the paucibacillary form of TB to the ACS syndrome, then it means that the way respiratory complications are treated in sickle cell disease should be reconsidered.
- In this case, it can be assumed that the inflammatory period of TB can affect the course of SCD, but further research needs to be conducted to confirm this assumption.
In summary, the results of the development of this ultra-sensitive molecular test provide us with the unseen picture of M. tuberculosis positivity in America. However, this is only preliminary information, which requires further investigation using the prospective approach, including the correlation between clinical manifestations, imaging techniques, immunology, and microbiology. Although it can be clearly seen that there are a number of positive cases of TB-DNA among both US-born individuals and patients with sickle cell disease, the contagiousness and the course of these diseases have yet to be revealed.
Reference:
Jones-López, E.C., Miller, N.S., Orr, B. et al. Unexpected detection of Mycobacterium tuberculosis DNA in US-born patients in putative association with clinical syndromes. Nat Commun 17, 2709 (2026). https://doi.org/10.1038/s41467-026-70890-6
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.